Aug 12, 2020
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Dec 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Nov 13, 2019
Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
Oct 03, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight(TM) Human Liver Disease platform
Sep 25, 2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
Sep 04, 2019
Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
Aug 12, 2019
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
Aug 08, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
Jun 24, 2019
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
May 22, 2019
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH
May 01, 2019
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Apr 11, 2019
89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
Jan 03, 2019
89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer
Oct 25, 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Jun 25, 2018
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Jan 17, 2018
Researchers Discover Structure of Anti-Aging Hormone
Sep 11, 2017
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)